The Mini-Mental Parkinson's (MMP) as a cognitive screening tool in people with Parkinson's disease

Robert Caslake, Fiona Summers, Douglas McConachie, Catriona Ferris, Joanna Gordon, Clare Harris, Linda Caie, Carl Counsell

Research output: Contribution to journalArticle

8 Citations (Scopus)
3 Downloads (Pure)

Abstract

Introduction Cognitive decline is common in Parkinson's disease (PD) but may not be adequately identified by the mini-mental state examination (MMSE), which is better suited to Alzheimer's disease. The mini-mental Parkinson (MMP) examination is a cognitive screening tool designed in French specifically for PD. We aimed to establish the validity and reliability of the English language version of the MMP compared with the MMSE. Methods People with various stages of PD underwent testing with the MMP and MMSE, which was then compared with a reference standard battery of neuropsychological tests to identify those with significant cognitive impairment. Results Forty-nine patients were recruited. Both the MMP and MMSE were significantly correlated with scores on all the neuropsychological tests in the validation battery. The median MMP score was proportionally lower (80% of maximum) than the MMSE (90% of maximum) in PD patients with cognitive impairment and those with prior neuropsychiatric complications but there was no difference between the MMP and MMSE in areas under the curves (0.84) for detecting cognitive impairment. Test-retest reliability of the MMP was good (intra-class correlation coefficient 0.793). An MMP of 28 or lower out of 32 detected cognitive impairment with 87% sensitivity and 76% specificity. Discussion The English language version of the MMP has now been validated. It detects more cognitive deficits in PD patients than the MMSE and identifies significant cognitive impairment in those with PD at least as well as the MMSE.
Original languageEnglish
Pages (from-to)273-279
Number of pages7
JournalCurrent Aging Science
Volume6
Issue number3
Early online date14 Jun 2013
DOIs
Publication statusPublished - 30 Nov 2013

Fingerprint

Parkinson Disease
Neuropsychological Tests
Reproducibility of Results
Language
Mentally Ill Persons
Area Under Curve
Cognitive Dysfunction
Alzheimer Disease
Sensitivity and Specificity

Keywords

  • cognition disorders
  • diagnosis
  • MMP
  • MMSE
  • neuropsychological tests
  • Parkinson's disease
  • screening tests

Cite this

The Mini-Mental Parkinson's (MMP) as a cognitive screening tool in people with Parkinson's disease. / Caslake, Robert; Summers, Fiona; McConachie, Douglas; Ferris, Catriona; Gordon, Joanna; Harris, Clare; Caie, Linda; Counsell, Carl.

In: Current Aging Science, Vol. 6, No. 3, 30.11.2013, p. 273-279.

Research output: Contribution to journalArticle

Caslake, Robert ; Summers, Fiona ; McConachie, Douglas ; Ferris, Catriona ; Gordon, Joanna ; Harris, Clare ; Caie, Linda ; Counsell, Carl. / The Mini-Mental Parkinson's (MMP) as a cognitive screening tool in people with Parkinson's disease. In: Current Aging Science. 2013 ; Vol. 6, No. 3. pp. 273-279.
@article{281faf4425df4cd0830a553616a82da8,
title = "The Mini-Mental Parkinson's (MMP) as a cognitive screening tool in people with Parkinson's disease",
abstract = "Introduction Cognitive decline is common in Parkinson's disease (PD) but may not be adequately identified by the mini-mental state examination (MMSE), which is better suited to Alzheimer's disease. The mini-mental Parkinson (MMP) examination is a cognitive screening tool designed in French specifically for PD. We aimed to establish the validity and reliability of the English language version of the MMP compared with the MMSE. Methods People with various stages of PD underwent testing with the MMP and MMSE, which was then compared with a reference standard battery of neuropsychological tests to identify those with significant cognitive impairment. Results Forty-nine patients were recruited. Both the MMP and MMSE were significantly correlated with scores on all the neuropsychological tests in the validation battery. The median MMP score was proportionally lower (80{\%} of maximum) than the MMSE (90{\%} of maximum) in PD patients with cognitive impairment and those with prior neuropsychiatric complications but there was no difference between the MMP and MMSE in areas under the curves (0.84) for detecting cognitive impairment. Test-retest reliability of the MMP was good (intra-class correlation coefficient 0.793). An MMP of 28 or lower out of 32 detected cognitive impairment with 87{\%} sensitivity and 76{\%} specificity. Discussion The English language version of the MMP has now been validated. It detects more cognitive deficits in PD patients than the MMSE and identifies significant cognitive impairment in those with PD at least as well as the MMSE.",
keywords = "cognition disorders, diagnosis, MMP, MMSE, neuropsychological tests, Parkinson's disease, screening tests",
author = "Robert Caslake and Fiona Summers and Douglas McConachie and Catriona Ferris and Joanna Gordon and Clare Harris and Linda Caie and Carl Counsell",
note = "ACKNOWLEDGEMENTS The PINE pilot study was funded by the BMA Doris Hillier Award.",
year = "2013",
month = "11",
day = "30",
doi = "10.2174/18746098112059990030",
language = "English",
volume = "6",
pages = "273--279",
journal = "Current Aging Science",
issn = "1874-6098",
publisher = "Bentham Science Publishers",
number = "3",

}

TY - JOUR

T1 - The Mini-Mental Parkinson's (MMP) as a cognitive screening tool in people with Parkinson's disease

AU - Caslake, Robert

AU - Summers, Fiona

AU - McConachie, Douglas

AU - Ferris, Catriona

AU - Gordon, Joanna

AU - Harris, Clare

AU - Caie, Linda

AU - Counsell, Carl

N1 - ACKNOWLEDGEMENTS The PINE pilot study was funded by the BMA Doris Hillier Award.

PY - 2013/11/30

Y1 - 2013/11/30

N2 - Introduction Cognitive decline is common in Parkinson's disease (PD) but may not be adequately identified by the mini-mental state examination (MMSE), which is better suited to Alzheimer's disease. The mini-mental Parkinson (MMP) examination is a cognitive screening tool designed in French specifically for PD. We aimed to establish the validity and reliability of the English language version of the MMP compared with the MMSE. Methods People with various stages of PD underwent testing with the MMP and MMSE, which was then compared with a reference standard battery of neuropsychological tests to identify those with significant cognitive impairment. Results Forty-nine patients were recruited. Both the MMP and MMSE were significantly correlated with scores on all the neuropsychological tests in the validation battery. The median MMP score was proportionally lower (80% of maximum) than the MMSE (90% of maximum) in PD patients with cognitive impairment and those with prior neuropsychiatric complications but there was no difference between the MMP and MMSE in areas under the curves (0.84) for detecting cognitive impairment. Test-retest reliability of the MMP was good (intra-class correlation coefficient 0.793). An MMP of 28 or lower out of 32 detected cognitive impairment with 87% sensitivity and 76% specificity. Discussion The English language version of the MMP has now been validated. It detects more cognitive deficits in PD patients than the MMSE and identifies significant cognitive impairment in those with PD at least as well as the MMSE.

AB - Introduction Cognitive decline is common in Parkinson's disease (PD) but may not be adequately identified by the mini-mental state examination (MMSE), which is better suited to Alzheimer's disease. The mini-mental Parkinson (MMP) examination is a cognitive screening tool designed in French specifically for PD. We aimed to establish the validity and reliability of the English language version of the MMP compared with the MMSE. Methods People with various stages of PD underwent testing with the MMP and MMSE, which was then compared with a reference standard battery of neuropsychological tests to identify those with significant cognitive impairment. Results Forty-nine patients were recruited. Both the MMP and MMSE were significantly correlated with scores on all the neuropsychological tests in the validation battery. The median MMP score was proportionally lower (80% of maximum) than the MMSE (90% of maximum) in PD patients with cognitive impairment and those with prior neuropsychiatric complications but there was no difference between the MMP and MMSE in areas under the curves (0.84) for detecting cognitive impairment. Test-retest reliability of the MMP was good (intra-class correlation coefficient 0.793). An MMP of 28 or lower out of 32 detected cognitive impairment with 87% sensitivity and 76% specificity. Discussion The English language version of the MMP has now been validated. It detects more cognitive deficits in PD patients than the MMSE and identifies significant cognitive impairment in those with PD at least as well as the MMSE.

KW - cognition disorders

KW - diagnosis

KW - MMP

KW - MMSE

KW - neuropsychological tests

KW - Parkinson's disease

KW - screening tests

U2 - 10.2174/18746098112059990030

DO - 10.2174/18746098112059990030

M3 - Article

VL - 6

SP - 273

EP - 279

JO - Current Aging Science

JF - Current Aging Science

SN - 1874-6098

IS - 3

ER -